Celecoxib-d7

Celecoxib-d7 is the deuterium labeled Celecoxib. Celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM[1][2].

Product Specifications

CAS Number

[544686-21-7]

Product Name Alternative

SC 58635-d7

UNSPSC

12352005

Hazard Statement

H360, H373, H411

Target

COX

Type

Isotope-Labeled Compounds

Related Pathways

Immunology/Inflammation

Field of Research

Inflammation/Immunology; Cancer

Purity

99.58

Solubility

10 mM in DMSO|DMSO : ≥ 76mg/mL|Ethanol : ≥ 33mg/mL

Smiles

NS(C1=CC=C(C=C1)N2C(C3=C(C([2H])=C(C([2H])=C3[2H])C([2H])([2H])[2H])[2H])=CC(C(F)(F)F)=N2)(=O)=O

Molecular Formula

C17H7D7F3N3O2S

Molecular Weight

388.42

Precautions

H360, H373, H411

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Liu DB, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin. 2012 May;33 (5) :682-90.|[3]Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib) . J Med Chem. 1997|[4]Hou XL, et al. Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone. Neural Regen Res. 2015 Nov;10 (11) :1836-40.|[5]Suri A, et al. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. Oncotarget. 2016 Apr 8.|[6]Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10 (8) :3622-3635.|[7]Liu C, et al. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. Sci Rep. 2018 Mar 7;8 (1) :4108.